• Imugene begins VAXINIA trial for bile tract cancer

  • Jul 17 2024
  • Duración: 10 m
  • Podcast

Imugene begins VAXINIA trial for bile tract cancer

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong and strategic advisor Dr Yuman Fong sit down with Proactive’s Jonathan Jackson to discuss Professor Fong’s expertise and the latest company developments. Dr Fong is a world-renowned cancer researcher, physician and surgeon whose clinical work has focused on OV for more than 30 years. He is the inventor of OV CF33. Imugene has dosed the first patient in its trial for bile tract cancer (cholangiocarcinoma) patients. The MAST (metastatic advanced solid tumours) Phase 1 trial has been expanded due to early responses in gastrointestinal cancers, particularly cholangiocarcinoma, using Imugene’s cancer-killing virus CF33, known as VAXINIA. The trial, held at St Vincent’s Hospital, Melbourne, Australia, expects to enrol 10 patients. Interim results showed positive responses in gastrointestinal cancers, including a complete response in bile tract cancer. The trial's fifth cohort of both arms has cleared and the sixth high-dose cohort is now open. Chong expressed optimism about VAXINIA's potential in bile tract cancer, highlighting the trial's advancement to higher doses to gather key data. In November 2023, the US FDA granted fast-track designation to VAXINIA MAST for bile tract cancer, enabling closer cooperation to expedite the approval process. Bile tract cancer is a rare and challenging disease, often responding poorly to immunotherapy. A recent study reported a complete response in a patient after receiving a mid-dose of IT-administered VAXINIA monotherapy, with no safety signals observed. The Phase 1 MAST trial has progressed through monotherapy dose escalation cohorts and includes a combination study with pembrolizumab. The CF33 virus, developed by City of Hope, has shown preclinical effectiveness in shrinking various cancer tumours. #ProactiveInvestors #Imugene #ASX #OTC #CancerResearch, #BileTractCancer, #Cholangiocarcinoma, #VAXINIA, #Oncology, #ClinicalTrial, #MASTTrial, #FDAFastTrack, #InnovativeTreatment, #GastrointestinalCancer, #CancerTreatment, #LeslieChong, #StVincentsHospital, #Melbourne, #Immunotherapy, #CheckpointInhibitor, #Pembrolizumab, #CF33Virus, #CityOfHope #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
    Más Menos
Empresas y Profesiones Economía Finanzas Personales Política y Gobierno
Más Menos

Lo que los oyentes dicen sobre Imugene begins VAXINIA trial for bile tract cancer

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles